15,406 Shares in OraSure Technologies, Inc. (NASDAQ:OSUR) Purchased by Rpo LLC

Rpo LLC purchased a new stake in OraSure Technologies, Inc. (NASDAQ:OSUR) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 15,406 shares of the medical instruments supplier’s stock, valued at approximately $56,000.

Several other large investors have also recently bought and sold shares of OSUR. ExodusPoint Capital Management LP grew its position in shares of OraSure Technologies by 1,007.1% in the fourth quarter. ExodusPoint Capital Management LP now owns 168,941 shares of the medical instruments supplier’s stock valued at $610,000 after purchasing an additional 153,681 shares during the last quarter. Geode Capital Management LLC boosted its stake in OraSure Technologies by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 1,844,139 shares of the medical instruments supplier’s stock valued at $6,659,000 after purchasing an additional 46,325 shares during the period. O Shaughnessy Asset Management LLC grew its holdings in OraSure Technologies by 28.4% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 273,340 shares of the medical instruments supplier’s stock valued at $987,000 after buying an additional 60,510 shares in the last quarter. Orion Portfolio Solutions LLC increased its position in OraSure Technologies by 10.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 61,170 shares of the medical instruments supplier’s stock worth $221,000 after buying an additional 5,929 shares during the period. Finally, EntryPoint Capital LLC lifted its holdings in shares of OraSure Technologies by 259.6% during the fourth quarter. EntryPoint Capital LLC now owns 101,205 shares of the medical instruments supplier’s stock worth $365,000 after buying an additional 73,061 shares in the last quarter. 93.50% of the stock is owned by institutional investors.

Insider Transactions at OraSure Technologies

In other news, Director John P. Kenny purchased 47,659 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was bought at an average price of $3.17 per share, with a total value of $151,079.03. Following the acquisition, the director now owns 70,915 shares in the company, valued at approximately $224,800.55. The trade was a 204.93 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kenneth J. Mcgrath purchased 64,000 shares of OraSure Technologies stock in a transaction that occurred on Thursday, February 27th. The shares were purchased at an average price of $3.15 per share, for a total transaction of $201,600.00. Following the transaction, the chief financial officer now directly owns 371,013 shares in the company, valued at $1,168,690.95. This represents a 20.85 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 190,284 shares of company stock valued at $600,348. 3.40% of the stock is owned by corporate insiders.

OraSure Technologies Price Performance

OraSure Technologies stock opened at $3.37 on Thursday. The firm has a market cap of $252.08 million, a PE ratio of 22.47 and a beta of -0.02. The stock’s fifty day moving average price is $3.66 and its two-hundred day moving average price is $3.86. OraSure Technologies, Inc. has a one year low of $2.69 and a one year high of $6.35.

OraSure Technologies announced that its Board of Directors has authorized a share buyback plan on Monday, March 24th that allows the company to repurchase $40.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to buy up to 15.6% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.